In the wake of the GLP-1 revolution, a Sydney biotech is quietly assembling a different kind of answer to Type 2 diabetes — not a rival to Ozempic, but a complement to it, and perhaps a successor. Myopharm, founded by a former Novartis and Pfizer executive alongside a veteran drug developer, has built TriGlytza from three familiar molecules, betting that the inflammation underlying diabetes has been underserved by the blockbusters that dominate the market. As the largest patent cliff in pharmaceutical history approaches, the company is positioning itself not merely as a treatment innovator, bu
Forbes Australia
· Jun 12, 2026
· technology
· 7 min read
High
Sourcing: Verified
Sydney biotech Myopharm eyes post-Ozempic market with diabetes drug combo
◉
Health & Medicine
8358 related articles
Retatrutide: Eli Lilly's Triple-Action Weight-Loss Drug Poised to Resh…
The Economic Times · 100% match
Eli Lilly Seeks FDA Approval for Tirzepatide as Weight-Loss Treatment
Interesting Engineering · 99% match
Eli Lilly's Oral GLP-1 Pill Shows Promise for Diabetes and Weight Loss
TODAY · 99% match
Eli Lilly Seeks FDA Approval for Tirzepatide as Weight Loss Drug
ScienceAlert · 99% match
Moderna's personalized mRNA melanoma vaccine shows promise in preventi…
CBS News · 99% match
Related Coverage
The Guardian · Aug 24
UK approves daily GLP-1 pill for diabetes and weight loss amid counterfeit drug warnings
Foundayo, a new daily pill treating diabetes and aiding weight loss, launches in UK pharmacies Monday. Pharmacists welco…
Mirage News · Aug 24 Study reveals type 2 diabetes in lean Africans requires different treatment approachResearch reveals type 2 diabetes in lean Africans stems from insulin deficiency, not resistance, yet they receive the sa…
Mirage News · Aug 24 Australian researchers identify existing drugs to slow rare childhood dementiaAustralian researchers identified nine existing TGA-approved medicines that could slow brain damage in children with San…
The New Indian Express · Aug 24 Odisha leads national push to prevent metabolic liver disease affecting 1 in 3 IndiansLeading gastroenterology and hepatology experts convened in Odisha to finalize national guidelines for preventing metabo…
Bias & Framing
⚖
Article presents favorable coverage of Myopharm's diabetes drug with minimal critical scrutiny, relying heavily on founder claims and anecdotal investor testimonials without independent verification.
Bias Direction
center-right
Confidence
HIGH
Promotional framing that positions Myopharm as a promising solution to an urgent market need. Uses founder's optimistic narrative as primary lens, emphasizing market opportunity and investor enthusiasm rather than scientific evidence or regulatory risks.
scramble to find
blockbuster
mop up what's left
had their day
resonated with investors
fast-track approval process
Independent medical/scientific experts evaluating TriGlytza's efficacy claims
Regulatory or clinical trial data substantiating the drug's advantages
Skeptical analysis of market timing and competitive landscape
Patient perspectives or real-world treatment outcomes
Potential risks or limitations of the combination therapy approach
Competing drugs or alternative approaches in development
Analysis of founder's track record or previous ventures
Geopolitical Impact
🌎
Australian biotech Myopharm's diabetes drug positions itself as post-GLP-1 complement, with minimal geopolitical implications but reflects growing competition in high-value pharma markets across Asia-Pacific and US.
Escalation Risk
low
Confidence
HIGH
Australia
Singapore
China
Hong Kong
United States
Reflects shift toward Asia-Pacific biotech innovation and capital flows; Australian company seeking regional and US validation suggests growing confidence in non-traditional pharma hubs. No major power realignment; primarily commercial competition within established pharmaceutical ecosystem.
Economic Lens
📈
Sydney biotech Myopharm raises $5M for TriGlytza diabetes drug targeting treatment failures post-GLP-1 era, positioning for ASX listing in H2 2026 in a $100B+ global diabetes market.
Market Signal
bullish
Confidence
MED
Pharmaceutical & Biotechnology
Healthcare
Capital Markets (ASX)
Medical Devices/Therapeutics
Potential new treatment option for Type 2 diabetes patients who fail first-line therapies or GLP-1 drugs (18% of users). Could improve health outcomes for poorly controlled diabetics and reduce treatment burden, though availability and cost dependent on regulatory approval and pricing.
Regulatory bodies (TGA, FDA) will need to evaluate efficacy and safety in Phase-2a trials. Patent cliff management for GLP-1 drugs may prompt policy discussions around drug pricing, market competition, and healthcare access. ASX listing will trigger corporate governance and disclosure requirements.